[SSY3] 特別シンポジウム3（YECジョイント企画）
Global pharma が見据える将来戦略

[SSY3-2] Building on Partnership to Deliver New Treatment Options

^○Marie-Pierre Hellio Le Graverand-Gastineau (Development Japan, Pfizer Japan Inc.)

Marie-Pierre is Vice President and Head of Development Japan. In this role, she leads the Global Product Development organization responsible for drug development in Japan. She most recently served as the Medicine Team Lead for Xeljanz®, where she oversaw the global late-stage development in several indications for the rheumatology, dermatology and gastroenterology franchises. In 2012, she was appointed Head of Clinical Research in Development Japan, where she was accountable for the acquisition of marketing authorization in Japan for all development products across primary care, oncology and specialty care conditions.
During her 15-year career at Pfizer, she has held a number of leadership positions, including Medicine Team Lead for cindunistat; Clinical Development and Medical Affairs Lead for Xiapex®; and Global Clinical Lead for multiple drug development candidates in the Inflammation and Pain Therapeutic Areas.
Marie-Pierre has authored or co-authored more than 200 publications and is the recipient of numerous medical awards and fellowships. She earned her MD and DSc from the Université Claude Bernard in Lyon, France, and her PhD in Molecular Biology from the University of Calgary in Alberta, Canada. She completed her post-doctoral fellowship at McGill University in Montreal, Canada.